RU2156239C2 - Замещенные 4-(1,2,3,4-тетрагидро-1-нафталинил)-1н-имидазолы и 4-(2,3-дигидро-1н-инден-1-ил)-1н-имидазолы, способы их получения и фармацевтическая композиция на их основе - Google Patents

Замещенные 4-(1,2,3,4-тетрагидро-1-нафталинил)-1н-имидазолы и 4-(2,3-дигидро-1н-инден-1-ил)-1н-имидазолы, способы их получения и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2156239C2
RU2156239C2 RU95120582/04A RU95120582A RU2156239C2 RU 2156239 C2 RU2156239 C2 RU 2156239C2 RU 95120582/04 A RU95120582/04 A RU 95120582/04A RU 95120582 A RU95120582 A RU 95120582A RU 2156239 C2 RU2156239 C2 RU 2156239C2
Authority
RU
Russia
Prior art keywords
tetrahydro
imidazole
naphthalenyl
pharmaceutically acceptable
acceptable acids
Prior art date
Application number
RU95120582/04A
Other languages
English (en)
Russian (ru)
Other versions
RU95120582A (ru
Inventor
ЖЕЕР Жан-Пьер
МОТ Женевьев
ДИФФЕРДИНГ Эдмон
ЭНИШАР Жан-Пьер
Original Assignee
Юцб С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юцб С.А. filed Critical Юцб С.А.
Publication of RU95120582A publication Critical patent/RU95120582A/ru
Application granted granted Critical
Publication of RU2156239C2 publication Critical patent/RU2156239C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU95120582/04A 1994-12-14 1995-12-13 Замещенные 4-(1,2,3,4-тетрагидро-1-нафталинил)-1н-имидазолы и 4-(2,3-дигидро-1н-инден-1-ил)-1н-имидазолы, способы их получения и фармацевтическая композиция на их основе RU2156239C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425211.1A GB9425211D0 (en) 1994-12-14 1994-12-14 Substituted 1H-imidazoles
GB9425211.1 1994-12-14

Publications (2)

Publication Number Publication Date
RU95120582A RU95120582A (ru) 1997-11-10
RU2156239C2 true RU2156239C2 (ru) 2000-09-20

Family

ID=10765918

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95120582/04A RU2156239C2 (ru) 1994-12-14 1995-12-13 Замещенные 4-(1,2,3,4-тетрагидро-1-нафталинил)-1н-имидазолы и 4-(2,3-дигидро-1н-инден-1-ил)-1н-имидазолы, способы их получения и фармацевтическая композиция на их основе

Country Status (26)

Country Link
US (1) US5658938A (enExample)
EP (1) EP0717037A1 (enExample)
JP (1) JPH08208622A (enExample)
KR (1) KR960022474A (enExample)
CN (1) CN1054376C (enExample)
AR (1) AR002257A1 (enExample)
AU (1) AU693614B2 (enExample)
BG (1) BG63043B1 (enExample)
BR (1) BR9505815A (enExample)
CA (1) CA2165133A1 (enExample)
CZ (1) CZ327195A3 (enExample)
EE (1) EE9500064A (enExample)
FI (1) FI955927A7 (enExample)
GB (1) GB9425211D0 (enExample)
HU (1) HUT73980A (enExample)
IL (1) IL116325A (enExample)
IS (1) IS4311A (enExample)
MX (1) MX9505063A (enExample)
NO (1) NO305316B1 (enExample)
NZ (1) NZ280646A (enExample)
PL (1) PL311736A1 (enExample)
RO (1) RO113346B1 (enExample)
RU (1) RU2156239C2 (enExample)
SK (1) SK155095A3 (enExample)
TW (1) TW303362B (enExample)
ZA (1) ZA9510554B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) * 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
CA2408290A1 (en) 2000-05-08 2001-11-15 Orion Corporation New polycyclic indanylimidazoles with alpha2 adrenergic activity
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
AU2007209382A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of CNS disorders
WO2008046757A1 (en) * 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
DE602007005671D1 (de) * 2006-10-19 2010-05-12 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
KR101176700B1 (ko) * 2006-11-02 2012-08-23 에프. 호프만-라 로슈 아게 미량 아민 결합된 수용체의 조절자로서 치환된 2-이미다졸
JP2010510184A (ja) * 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
AU2007332641A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
NZ578260A (en) * 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
KR20090113326A (ko) * 2007-02-13 2009-10-29 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제
MX2009008776A (es) * 2007-02-13 2009-08-25 Schering Corp Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
JP5130305B2 (ja) * 2007-02-15 2013-01-30 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしての２−アミノオキサゾリン
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
EP2173719A1 (en) * 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
JP2010534701A (ja) * 2007-07-27 2010-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒリガンドとしての２−アゼチジンメタンアミン及び２−ピロリジンメタンアミン
KR20100039429A (ko) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도
JP5341084B2 (ja) * 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
AU2009273324A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
EP2323734A1 (en) * 2008-08-04 2011-05-25 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
US9181230B2 (en) 2012-01-12 2015-11-10 Hoffmann-La Roche Inc. Morpholine compounds and uses thereof
MX363362B (es) 2012-09-14 2019-03-21 Hoffmann La Roche Derivados de pirazol carboxamida como moduladores de los receptores asociados con las aminas traza (taar) para uso en el tratamiento de varios trastornos, tales como depresión, diabetes y enfermedades de parkinson.
KR101676208B1 (ko) 2012-09-17 2016-11-14 에프. 호프만-라 로슈 아게 트라이아졸 카복스아미드 유도체
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CN107001259B (zh) 2014-08-27 2019-12-06 豪夫迈·罗氏有限公司 作为taar配体的取代的氮杂环丁烷衍生物
CA2953040A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders
EA039557B1 (ru) * 2016-03-17 2022-02-10 Фмк Корпорейшн Способ превращения s-энантиомера в его рацемическую форму
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048972A (ja) * 1983-08-25 1985-03-16 Dai Ichi Seiyaku Co Ltd テトラヒドロナフタレン誘導体
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
JPH04210680A (ja) * 1990-12-01 1992-07-31 Nissan Chem Ind Ltd イミダゾール誘導体および植物生長調節剤
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles

Also Published As

Publication number Publication date
EE9500064A (et) 1996-06-17
BG63043B1 (bg) 2001-02-28
HUT73980A (en) 1996-10-28
NO305316B1 (no) 1999-05-10
NO955034L (no) 1996-06-17
FI955927L (fi) 1996-06-15
BG100208A (bg) 1996-07-31
IS4311A (is) 1996-06-15
EP0717037A1 (fr) 1996-06-19
CN1054376C (zh) 2000-07-12
CZ327195A3 (en) 1996-07-17
IL116325A0 (en) 1996-03-31
CN1133837A (zh) 1996-10-23
SK155095A3 (en) 1997-02-05
KR960022474A (ko) 1996-07-18
RO113346B1 (ro) 1998-06-30
FI955927A0 (fi) 1995-12-11
NZ280646A (en) 1996-08-27
AU693614B2 (en) 1998-07-02
AU4036895A (en) 1996-06-20
HU9503549D0 (en) 1996-02-28
PL311736A1 (en) 1996-06-24
CA2165133A1 (en) 1996-06-15
JPH08208622A (ja) 1996-08-13
BR9505815A (pt) 1998-01-06
US5658938A (en) 1997-08-19
GB9425211D0 (en) 1995-02-15
NO955034D0 (no) 1995-12-12
AR002257A1 (es) 1998-03-11
FI955927A7 (fi) 1996-06-15
IL116325A (en) 1999-10-28
MX9505063A (es) 1997-01-31
TW303362B (enExample) 1997-04-21
ZA9510554B (en) 1996-06-13

Similar Documents

Publication Publication Date Title
RU2156239C2 (ru) Замещенные 4-(1,2,3,4-тетрагидро-1-нафталинил)-1н-имидазолы и 4-(2,3-дигидро-1н-инден-1-ил)-1н-имидазолы, способы их получения и фармацевтическая композиция на их основе
CA2012628C (fr) Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CA1237723A (en) Antidepressant 1,2,4-triazolone compounds
US5001134A (en) Piperidines, processes of preparation and medications containing them
MXPA02006499A (es) Derivados de fenilpiperazinilo.
US4080330A (en) Phenylindolines and process for their production
JPH0633254B2 (ja) Ｎ−置換ジフエニルピペリジン類
US4314943A (en) Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
JPH0819064B2 (ja) インダンの新誘導体、それらの製造法及び薬剤としての使用
JPS5967270A (ja) イソキノリン誘導体の製法
JPS6130674B2 (enExample)
JP2856912B2 (ja) Ｃｎｓ活性を示すトラゾドンのアルキル誘導体
US4826845A (en) 3(2H)-pyridazinones and pharmaceutical compositions thereof
Deák et al. A new type of anticonvulsant: 1-aryl-3-oxotetrahydroisoquinolines
FI81795C (fi) Foerfarande foer framstaellning av substituerade isokinolinderivat.
US6248907B1 (en) N-([1,4]benzodioxan-2-ylmethyl)-N-(3-chloro-1-propyl)-amine
JP2531517B2 (ja) ナフタレンスルホンアミド誘導体
US4495352A (en) Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
JPH07603B2 (ja) イソキノリンスルホンアミド誘導体
JPH0742276B2 (ja) 新規ｎ置換３，４―ジヒドロピリミジン誘導体および血管拡張剤
US4105768A (en) Hypotensive substituted 1,2,4-triazoles
US4022905A (en) Benzylidene hydrazino-1,2,4-triazoles, pharmaceuticals therewith, and method of use
CA1187079A (en) 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indole derivatives and their preparation
JPS5942370A (ja) イソキノリン誘導体及びその製造方法、並びに該誘導体を含有する医薬
JPS5942369A (ja) イソキノリン誘導体及びその製造方法、並びに該誘導体を含有する医薬